Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/17/2019 |
| Start Date: | March 8, 2019 |
| End Date: | March 2021 |
| Contact: | Matthew Hellmann, MD |
| Email: | hellmanm@mskcc.org |
| Phone: | 646-888-4863 |
Characterization of Mechanism of Response to PD-1 Blockade in NSCLC: A Pilot Study
The purpose of this study is to attempt to obtain an on-treatment biopsy in participants with
non-small cell lung cancer who are receiving standard treatment with a drug that targets the
PD-1 or PD-L1 protein.
non-small cell lung cancer who are receiving standard treatment with a drug that targets the
PD-1 or PD-L1 protein.
Inclusion Criteria:
- Pathologically confirmed newly diagnosed or recurrent advanced Non Small Cell Lung
Cancer/NSCLC that is PI-L1 high by immunohistochemistry (PD-L1 >/= 50%)
- Intended treatment with a PD-(L)1 inhibitor
- Age >/= 18 years
- Karnofsky Performance Status >/= 70% and medically fit to undergo a biopsy procedure
Exclusion Criteria:
- Any medical condition or any sites of disease that would preclude a biopsy
- Pregnant or breastfeeding women
- Cognitively impairment affecting ability to understand and provide informed consent
- Prior PD-(L)1 blockade treatment
- Chemotherapy within 6 months prior to enrollment
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Phone: 646-888-4863
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
